Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
Conclusions/interpretationThe CANVAS Program demonstrated that canagliflozin increased the risk of amputation (mainly minor) in this study population. Anticipated risk factors for amputation were identified, such as prior history of amputation, peripheral vascular disease and neuropathy, but no specific aetiological mechanism or at-risk subgroup for canagliflozin was identified.
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Brain | Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | Neurology | Peripheral Vascular Disease (PVD) | Study